CRISPR-Cas13d Exhibits Robust Antiviral Activity Against Seneca Valley Virus

Yu-Yuan Zhang; Ming-Xia Sun; Yuexiao Lian; Tong-Yun Wang; Mei-Yu Jia; Chaoliang Leng; Meng Chen; Yuan-Zhe Bai; Fandan Meng; Xue-Hui Cai; Yan-Dong Tang

doi:10.3389/fmicb.2022.835040

CRISPR-Cas13d Exhibits Robust Antiviral Activity Against Seneca Valley Virus

Front Microbiol. 2022 Feb 14:13:835040. doi: 10.3389/fmicb.2022.835040. eCollection 2022.

Authors

Affiliations

¹ State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, China.
² Guangdong Laboratory Animals Monitoring Institute and Guangdong Key Laboratory of Laboratory Animals, Guangzhou, China.
³ Henan Provincial Engineering and Technology Center of Animal Disease Diagnosis and Integrated Control, Nanyang Normal University, Nanyang, China.

Abstract

In recent years, Seneca Valley virus (SVV) as a newly identified pathogen of porcine vesicular disease spread quickly and has posed a potential threat to the swine industry in several countries resulting in economic losses. Considering the evolution of SVV, attention should be given to controlling SVV epidemics. So far there are no commercial vaccines or drugs available to combat SVV. Therefore, development of strategies for preventing and controlling SVV infection should be taken into account. In the current study, we evaluated whether the CRISPR-Cas13d system could be used as a powerful tool against SVV infection. Besides, selected crRNAs showed different capacity against SVV infection. Our study suggests the CRISPR-Cas13d system significantly inhibited SVV replication and exhibited potent anti-SVV activity. This knowledge may provide a novel alternative strategy to control epidemics of SVV in the future.

Keywords: CRISPR-Cas13d; CasRx; SVV; antiviral; virus.